Quantcast
Last updated on April 18, 2014 at 9:36 EDT

Latest Hodgkin's lymphoma Stories

2013-07-31 23:36:52

Gloria Rand - SEO Copywriter has joined the Leukemia & Lymphoma Society's Team in Training to run the 2014 Walt Disney World Marathon and raise money for blood cancer research. Oviedo, FL (PRWEB) July 31, 2013 Gloria Rand, SEO Copywriter & Social Media Consultant has committed to run the Walt Disney World Marathon on January 12, 2014 to benefit The Leukemia & Lymphoma Society (LLS). Ms. Rand will spend the next five months preparing for the 26.2 mile race with the help of...

2013-07-29 13:07:50

The incidence of a particular type of blood cancer is significantly higher in regions near facilities that release the chemical benzene into the environment. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. This and other studies like it will be critical to identifying and enacting public health policies to decrease or prevent cancer. Non-Hodgkin lymphoma has been on the rise over the past few decades as...

2013-07-29 10:49:47

Stable survival rates were observed for HIV-associated lymphoma patients during the antiretroviral therapy (ART) era in the US, according to a new study published July 26 in the Journal of the National Cancer Institute. Studies have shown that HIV infection increases the risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) and that incidence for many lymphoma types has not decreased in the ART era. Furthermore, lymphoma is the most frequent cancer-related cause of death among...

2013-07-24 16:23:55

WHITE PLAINS, N.Y., July 24, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced the appointment of Rosemarie Loffredo, an executive with a significant financial background, as its new chief administrative officer and chief financial officer. To view the multimedia assets associated with this release, please click...

2013-07-23 08:29:58

LLS Sponsors & Partners Unite in Mission to Focus on Blood Cancer Cures WHITE PLAINS, N.Y., July 23, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is working with more than 100 national partners and sponsors to realize a world without blood cancers through the Light The Night(®) (LTN) Walk (www.LightTheNight.org). Together with LLS, the corporate partners and sponsors are raising awareness and making a positive impact on the lives of patients today, by literally...

2013-07-22 12:26:59

The "Light The Night" Campaign has raised more than $1.8 million over 6 years SAN BERNARDINO, Calif., July 22, 2013 /PRNewswire/ -- Stater Bros. Charities and The Leukemia & Lymphoma Society concluded another successful "Light The Night" fundraising campaign in support of The Leukemia & Lymphoma Society's mission to raise awareness and funds against Leukemia, Hodgkin and Non-Hodgkin Lymphoma, Myeloma and Myelodysplastic Syndromes. This year, Stater Bros. Charities exceeded...

2013-07-17 08:27:19

Thousands Will Walk as One to Raise Funds to Stomp Out Blood Cancers in 2013 WHITE PLAINS, N.Y., July 17, 2013 /PRNewswire/ -- For the 14(th) year in a row, The Leukemia & Lymphoma Society (LLS) aims to stomp out blood cancer through the Light The Night(®) (LTN) Walk (www.LightTheNight.org). The LTN Walk is a powerful and unique fundraising campaign of LLS, which brings together families and communities to honor blood cancer survivors, as well as those lost to the disease, and...

2013-07-11 16:24:47

16-Year-Old San Antonio Man and Illinois Woman Win National Titles WHITE PLAINS, N.Y., July 11, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society's (LLS) 2013 Man & Woman of the Year campaign exceeded last year's record, raising $22.7 million for blood cancer research and patient services. In its 23(rd) year more than 850 candidates participated and collectively surpassed last year's fundraising record by $3.5 million. (Photo:...

2013-07-10 15:56:06

New study evaluates maximum tolerated dose and clinical response A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using...

2013-07-10 08:26:41

If approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma RARITAN, N.J., July 10, 2013 /PRNewswire/ -- Janssen Research & Development, LLC announced the submission of a New Drug Application for ibrutinib to the U.S. Food and Drug Administration (FDA) for its use in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and...